Treatment of lipid disorders in obesity

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 8, 2011, Pages 1069-1080

  Tonstad, Serena ^a   Després, Jean Pierre ^b  

^a Dept of Epidemiology Biostatistics   (United States)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

atherogenic; dyslipidemia; hyperlipidemia; lipid lowering drugs; metabolic syndrome; obesity; statins; weight loss surgery

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; ROSUVASTATIN; TRIACYLGLYCEROL;

ATHEROGENIC DYSLIPIDEMIA; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; FAMILIAL COMBINED HYPERLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; OBESITY; POSTPRANDIAL HYPERLIPIDEMIA; REVIEW; SURGICAL TECHNIQUE; WEIGHT LOSS SURGERY; WEIGHT REDUCTION;

ATHEROSCLEROSIS; BARIATRIC SURGERY; COMBINED MODALITY THERAPY; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIFE STYLE; OBESITY; WEIGHT LOSS;

EID: 80052469062     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.83     Document Type: Review

References (111)

1. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J. Clin. Endocrinol. Metab. 89, 2569-2575 (2004).
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 285, 2486-2497 (2001).
3. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006 Natl Health Stat. Report 5, 1-7 (2009).
4. Grundy SM. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am. J. Cardiol. 75, 45B-52B (1995).
5. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology 132, 2181-2190 (2007).
6. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 1225-1236 (2008).
7. Aguilera CM, Gil-Campos M, Canete R, Gil A. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin. Sci. 114, 183-193 (2008).
8. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J. Clin. Invest. 113, 1582-1458 (2004).
9. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131 (2002).
10. Yamashita H, Takenoshita M, Sakurai M et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc. Natl Acad. Sci. USA 98, 9116-9121 (2001).
11. Hill MJ, Metcalfe D, McTernan PG. Obesity and diabetes: lipids, 'nowhere to run to'. Clin. Sci. 116, 113-123 (2009).
12. Van Linthout S, Foryst-Ludwig A, Spillmann F et al. Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis 210, 438-444 (2010).
13. De Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat. Clin. Pract. Endocrinol. Metab. 4, 608-618 (2008).
14. Magkos F, Mohammed BS, Mittendorfer B. Effect of obesity on the plasma lipioprotein subclass profile in normoglycemic and normolipidemic men and women. Int. J. Obes. 32, 1655-1664 (2008).
15. Magkos F, Mittendorfer B. Gender differences in lipid metabolism and the effect of obesity. Obstet. Gynecol. Clin. N. Am. 36, 245-265 (2009).
16. Mooradian AD, Albert SG, Hass MJ. Low serum HDL-cholesterol in obese subjects with normal serum triglycerides: the role of insulin resistance and inflammatory cytokines. Diabetes Obes. Metab. 9, 441-443 (2007).
17. Lindström T, Kechagias S, Carlsson M, Nystrom FH. Transient increase in HDL-cholesterol during weight gain by hyperalimentation in healthy subjects. Obesity 19, 812-817 (2010).
18. Mooradian AD, Haas MJ, Wehmeier KR, Wong NCW. Obesity-related changes in high-density lipoprotein metabolism. Obesity 16, 1152-1160 (2008).
19. Zhang Y, McGillicuddy FC, Hindle CC et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 121, 1347-1355 (2010).
20. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375, 1634-1639 (2010).
21. Williams KJ, Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr. Opin. Lipidol. 21, 218-228 (2010).
22. Sørensen TIA, Virtue S, Vidal-Puig A. Obesity as a clinical and public health problem: is there a need for a new definition based on lipotoxicity effects? Biochim. Biophys. Acta 1801, 400-404 (2010).
23. Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP. Primary and secondary hypertriglyceridaemia. Curr. Drug Targets 10, 336-343 (2009).
24. Duane WC. Cholesterol metabolism in familial hypertriglyceridemia: effects of obesity versus triglyceride level. J. Lab. Clin. Med. 130, 635-642 (1997).
25. Hole I, Aastveit AH, Hammar N, Jungner I, Walldius G. Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein Mortality RISk study (AMORIS). Atherosclerosis 213, 299-305 (2010).
26. Kastelein JJ, van der Steeg WA, Holme I et al.; TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins and their ratios in relation to cardiovascular events with statin treatment. Circulation 117, 3002-3009 (2008).
27. Cui Y, Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161, 1413-1419 (2001).
28. Sniderman AD, Williams K, Contois JH et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes 4(3), 337-345 (2011).
29. Sniderman A, Williams K, de Graaf J. Non-HDL C equals apolipoprotein B: except when it does not! Curr. Opin. Lipidol. 21, 518-524 (2010).
30. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P et al. Body mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373, 1083-1096 (2009).
31. Després JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr. Res. Rev. 6, 137-159 (1993).
32. Yu B-L, Zhao S-P, Hu J-R. Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity. Obes. Rev. 11, 560-567 (2009).
33. Ståhlberg D, Rudling M, Angelin B et al. Hepatic cholesterol metabolism in human obesity. Hepatology 25, 1447-1450 (1997).
34. Dixon JB, O'Brien P. A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m2 Int. J. Obes. Relat. Metab. Disord. 25, 793-797 (2001).
35. Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch. Intern. Med. 153, 1093-1103 (1993).
36. Denke MA, Sempos CT, Grundy SM. Excess body weight. An under-recognized contributor to dyslipidemia in white American women. Arch. Intern. Med. 154, 401-410 (1994).
37. Brown RJ, Lagor WR, Sankaranaravanan S et al. Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins. Circ. Res. 107, 357-364 (2010).
38. Pihlajamäki J, Gylling H, Miettinen TA, Laakso M. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J. Lipid. Res. 45, 507-512 (2004).
39. Kolovou GD, Kostakou PM, Anagnostopoulou KK. Familial hypercholesterolemia and triglyceride metabolism. Int. J. Cardiol. 147, 349-358 (2011).
40. Hogue JC, Lamarche B, Gaudet D et al. Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis 190, 429-435 (2007).
41. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a huGE association review. Am. J. Epidemiol. 160, 421-429 (2004).
42. Gaudet D, Vohl M-C, Perron P et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 97, 871-877 (1998).
43. Hopkins PN, Heiss G, Ellison RC et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 108, 519-523 (2003).
44. Van Himbergen TM, Otokozawa S, Matthan NR et al. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. Arterioscler. Thromb. Vasc. Biol. 30, 113-120 (2010).
45. Brouwers MCGJ, de Graaf J, van Greevenbroek MMJ, Schaper N, Stehouwer CDA, Stalenhoef AFH. Novel drugs in familial combined hyperlipidemia: lessons from Type 2 diabetes. Curr. Opin. Lipidol. 21, 530-538 (2010).
46. Van der Kallen CJ, Voors-Pette C, de Bruin TW. Abdominal obesity and expression of familial combined hyperlipidemia. Obes. Res. 12, 2054-2061 (2004).
47. Van der Vleuten GM, Veerkamp MJ et al. Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD. Atherosclerosis 183, 355-360 (2005).
48. Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412-423 (2009).
49. Tzotzas T, Evangelou P, Kiortsis DN. Obesity, weight loss and conditional cardiovascular risk factors. Obes. Rev. 12, e282-e289 (2011).
50. Retterstøl K, Hennig CB, Iversen PO. Improved plasma lipids and body weight in overweight/obese patients with type III hyperlipoproteinemia after 4 weeks on a low glycemic diet. Clin. Nutr. 28, 213-215 (2009).
51. Loveman E, Frampton GK, Shepherd J et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol. Assess. 15, 1-182 (2011).
52. Di Buono M, Hannah JS, Latzel LI, Jones PJH. Weight loss due to energy restriction suppresses cholesterol biosynthesis in overweight, mildly hypercholesterolemic men. J. Nutr. 129, 1545-1548 (1999).
53. Datillo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr. 56, 320-328 (1992).
54. The LOOK AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with Type 2 diabetes mellitus. Arch. Intern. Med. 170, 1566-1575 (2010).
55. Yatsuya H, Jeffery RW, Erickson DJ et al. Sex-specific HDL-cholesterol changes with weight loss and their association with anthropometric variables: the LIFE study. Obesity 19, 429-435 (2011).
56. Maraki MI, Aggelopoulou N, Christodoulou N et al. Lifestyle intervention leading to moderate weight loss normalizes postprandial triacylglycerolemia despite persisting obesity. Obesity 19, 968-976 (2011).
57. Nordmann AJ, Nordmann A, Briel M et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 166, 285-293 (2006).
58. Samaha FF, Foster GD, Makris AP. Low-carbohydrate diets, obesity, and metabolic risk factors for cardiovascular disease. Curr. Atheroscler. Rep. 9, 441-447 (2007).
59. Shai I, Schwarzfuchs D, Henkin Y et al.; for the Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229-241 (2008).
60. Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Engl. J. Med. 360, 859-873 (2009).
61. Foster GD, Wyatt HR, Hill JO et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet. Ann. Intern. Med. 153, 147-157 (2010).
62. Westman EC, Yancy WS Jr, Olsen MK, Dudley T, Guyton JR. Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int. J. Cardiol. 110, 212-216 (2006).
63. Seshadri P, Iqbal N, Stern L et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am. J. Med. 117, 398-405 (2004).
64. Volek JS, Phinney SD, Forsythe CE et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids 44, 297-309 (2009).
65. LeCheminant JD, Smith BK, Westman EC, Vernon MC, Donnelly JE. Comparison of a reduced carbohydrate and reduced fat diet for LDL, HDL, and VLDL subclasses during 9-months of weight maintenance subsequent to weight loss. Lipids Health Disease 9, 54 (2010).
66. Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM. Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. Am. J. Clin. Nutr. 20, 23-32 (2009).
67. Tay J, Brinkworth GD, Noakes M, Keogh J, Clifton PM. Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-cardohydrate diet in abdominally obese subjects. J. Am. Coll. Cardiol. 51, 59-67 (2008).
68. Larsen TM, Dalskov SM, van Baak M et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N. Engl. J. Med. 363, 2102-2113 (2010).
69. Vetter ML, Iqbal N, Volger S, Wadden TA. Long-term effects of low-carbohydrate versus low-fat diets in obese persons. Ann. Intern. Med. 152, 334-335 (2010).
70. Wu T, Gao X, Chen M, van Dam RM. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes. Rev. 10, 313-323 (2009).
71. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst. Rev. 4, CD003817 (2006).
72. Nakou ES, Filippatos TD, Kiortsis DN et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyeprlipidaemia. Expert Opin. Pharmacother. 9, 3151-3158 (2008).
73. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev. Cardiovasc. Ther. 8(12), 1777-1796 (2010).
74. Smith SR, Weissman NJ, Anderson CM et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245-256 (2010).
75. Wadden TA, Foreyt JP, Foster GD et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 19, 110-120 (2011).
76. James WP, Caterson ID, Coutinho W et al.; SCOUT investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363, 905-917 (2010).
77. Després J-P. Drug treatment for obesity. BMJ 322, 1379-1380 (2001).
78. NIH Consensus Development Panel: Gastrointestinal surgery for severe obesity. Ann. Intern. Med. 115, 956-961 (1991).
79. Yermilov I, McGory ML, Shekelle PW, Ko CY, Maggard MA. Appropriateness criteria for bariatric surgery: beyond the NIH guidelines. Obesity 17, 1521-1527 (2009).
80. Pontiroli AE, Laneri M, Veronelli A et al. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity; their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc. Diabetol. 8, 37 (2009).
81. Sjöström L, Narbro K, Sjöström CD et al.; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357, 741-752 (2007).
82. Sjöström L, Lindroos A-K, Peltonen M et al.; for the Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004).
83. Wolf AM, Beisiegel U. The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes. Surg. 17, 910-919 (2007).
84. Kim S, Richards WO. Long-term follow-up of the metabolic profiles in obese patients with Type 2 diabetes mellitus after Roux-en-Y gastric bypass. Ann. Surg. 251, 1049-1055 (2010).
85. Pihlajamäki J, Grönlund S, Simonen M et al. Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. Metabolism 59, 866-872 (2010).
86. Hofsø D, Nordstrand N, Johnson LK et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur. J. Endocrinol. 163, 735-745 (2010).
87. Asztalos BF, Swarbrick MM, Schaefer EJ et al. Effects of weight loss, induced by gastric bypass surgery, on HDL remodelling in obese women. J. Lipid Res. 51(8), 2405-2412 (2010).
88. Laimer MW, Engl J, Tschoner A et al. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids 44, 1125-1130 (2009).
89. Grundy SM, Cleeman JI, Merz CNB et al.; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110, 227-239 (2004).
90. Silventoinen K, Magnusson PK, Neovius M et al. Does obesity modify the effect of blood pressure on the risk of cardiovascular disease? A population-based cohort study of more than one million Swedish men. Circulation 118, 1637-1642 (2008).
91. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
92. Jamal M, Wenger R, Heitshusen D, Liao J, Samuel I. Resolution of hyperlipidemia follows surgical weight loss in patients undergoing Roux-en-Y gastric bypass surgery: a 6-year analysis of data. Surg. Obes. Relat. Dis. 7(4), 473-479 (2011).
93. Skottheim IB, Stormark K, Christensen H et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin. Pharmacol. Ther. 86, 311-318 (2009).
94. Skottheim IB, Jakobsen GS, Stormark K et al. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin. Pharmacol. Ther. 87, 699-705 (2010).
95. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 1760 000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
96. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann. Intern. Med. 152, 69-77 (2010).
97. Brunzell JD, Howard BV, Davidson M et al. Lipoprotein management in patients with cardiometabolic risk. Diabetes Care 31, 811-822 (2008).
98. Deedwania P, Barter P, Carmena R et al. Reduction of low-density- lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets Study. Lancet 368, 919-928 (2006).
99. Hoenig MR, Kostner KM, Read SJ, Walker PJ, Atherton JJ. Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. Endocr. Metab. Immune Disorder Drug Targets 7, 153-166 (2007).
100. Hoenig MR, Sellke FW. Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. Atherosclerosis 211, 260-265 (2010).
101. Miettinen TA, Gylling H, Strandberg T, Sarna S; for the Finnish 4S Investigators. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. BMJ 316, 1127-130 (1998).
102. Neil HA, Ceglarek U, Thiery J, Paul S, Farmer A, Holman RR. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in Type 2 diabetes: a randomized placebo controlled factorial trial. Atherosclerosis 213(2), 512-517 (2010).
103. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210, 353-361 (2010).
104. The ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
105. Barter PJ, Rye K-A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol. 28, 39-46 (2008).
106. Barter PJ, Caulfield M, Eriksson M et al.; ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
107. Christopher P. Cannon CP, Shah S Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363(25), 2406-2415 (2010).
108. Greeve J. Inhibition of the synthesis of apolipoprotein B-containing lipoproteins. Hanb. Exp. Pharmacol. 170, 483-517 (2005).
109. Filion KB, El Khoury F, Beilinski M, Schiller I, Dendukuri N, Brophy JM. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord. 10, 24 (2010).
110. Cohen JD, Cziraky MJ, Cai Q et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006 Am. J. Cardiol. 106, 969-975 (2010).
111. Cohen D. Rosiglitazone: what went wrong? BMJ 341, c4848 (2010).